A comparison of cycle control, efficacy, and side effects among healthy Thai women between two low-dose oral contraceptives containing 20 μg ethinylestradio1/75 μg gestodene (Meliane) and 30 μg ethinylestradio1/75 μg gestodene (Gynera®)

Contraception

Volumn 66, Issue 6, 2002, Pages 407-409

  Taneepanichskul, S ^a   Kriengsinyot, R ^a   Jaisamrarn, U ^a  

^a CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

Cycle control; Ethinylestradiol; Gestodene

Indexed keywords

ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; GESTODENE; ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; BREAKTHROUGH BLEEDING; BREAST TENDERNESS; CHLOASMA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; FEMALE; HUMAN; HUMAN EXPERIMENT; LOW DRUG DOSE; NAUSEA; SIDE EFFECT; SPOTTING; STATISTICAL SIGNIFICANCE; VERTIGO; VOMITING;

ADULT; BLOOD PRESSURE; BODY WEIGHT; CONTRACEPTIVES, ORAL; DIZZINESS; ETHINYL ESTRADIOL; FEMALE; HUMANS; MELANOSIS; MENSTRUAL CYCLE; NAUSEA; NORPREGNENES; THAILAND; UTERINE HEMORRHAGE; VOMITING;

EID: 0242317750     PISSN: 00107824     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0010-7824(02)00411-0     Document Type: Article

References (8)

1. Gast M.J., Grubb G. A review of cycle control with a low-dose oral contraceptive containing 75 μg gestodene and 20 μg ethinylestradiol. Gynecol Endocrinol. 12:(suppl 3):1998;31-37.
2. Reinprayoon D., Taneepanichskul S. Menstrual problems and side effects associated with long-term TCu 80 A IUD use in perimenopausal women. Contraception. 57:1998;471-479.
3. Endrikat J., Jaques M.A., Mayerhofer M., Pelissier C., Muller U., Dusterberg B. A twelve-month comparative clinical investigation of two low-dose oral contraceptives containing 20 μg ethinylestradiol/75 μg gestodene and 20 μg ethinylestradiol/150 μg desogestrel, with respect to efficacy, cycle control, and tolerance. Contraception. 52:1995;229-235.
4. Paoletti A.M., Orru M., Floris S., et al. Evidence that treatment with monophasic oral contraceptive formulation containing ethinylestradiol plus gestodene reduces bone resorption in young women. Contraception. 61:2000;259-263.
5. van Heusden A.M., Fauser B.C. Activity of the pituitary-ovarian axis in the pill-free interval during use of low-does combined oral contraceptives. Contraception. 59:1999;237-243.
6. An open label randomized study to evaluate the effects of seven monophasic oral contraceptive regimens on hemostasis variables. Contraception. 59:1999;345-355.
7. Serfaty D., Vree M.L. A comparison of the cycle control and tolerability of two ultra low dose oral contraceptives contain 20 micrograms ethinylestradiol and either 150 micrograms desogestrel or 75 micrograms gestodene. Eur J Contracept Reprod Health Care. 3:1998;179-189.
8. Lello S., Monterubbianesi M., Guardianelli F., Bianchi C., Simonelli C. Clinical trial of a monophasic estroprogestin oral formulation containing 20 μg ethinylestradiol and 75 μg gestodene. Gynecol Endocrinol. 15:2001;265-271.